platinum has been researched along with amifostine anhydrous in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Culo, F; Spellman, JM; Yuhas, JM | 1 |
| Adelstein, D; Bauer, L; Budd, GT; Bukowski, RM; Ganapathi, R; Gibson, V; McLain, D; Murthy, S; Sergi, J; Weick, J | 1 |
| Boven, E; Fichtinger-Schepman, AM; Korst, AE; van der Sterre, ML; van der Vijgh, WJ | 2 |
| Fichtinger-Schepman, AM; Gall, HE; Korst, AE; van der Sterre, ML; van der Vijgh, WJ; Vermorken, JB | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Navarro-Ruiz, NE | 1 |
1 review(s) available for platinum and amifostine anhydrous
| Article | Year |
|---|---|
Prevention of Platinum-Induced Hearing Loss in Children with Cancer.
Topics: Amifostine; Humans; Neoplasms; Ototoxicity; Platinum; Practice Guidelines as Topic; Thiosulfates | 2020 |
2 trial(s) available for platinum and amifostine anhydrous
| Article | Year |
|---|---|
Phase I study of WR-2721 and carboplatin.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Platinum; Thrombocytopenia | 1993 |
Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Cisplatin; DNA Adducts; Drug Interactions; Female; Half-Life; Hemofiltration; Humans; Leukocytes; Male; Middle Aged; Neoplasms; Platinum; Radiation-Protective Agents | 1998 |
4 other study(ies) available for platinum and amifostine anhydrous
| Article | Year |
|---|---|
The role of WR-2721 in radiotherapy and/or chemotherapy.
Topics: Alkylating Agents; Amifostine; Animals; Breast Neoplasms; Cyclophosphamide; Humans; In Vitro Techniques; Mechlorethamine; Melphalan; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Organothiophosphorus Compounds; Platinum; Rabbits; Radiation-Protective Agents; Rats; Time Factors | 1980 |
Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
Topics: Amifostine; Animals; Antineoplastic Agents; Body Temperature; Carboplatin; DNA Adducts; Drug Administration Schedule; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Platinum; Radiation-Protective Agents; Transplantation, Heterologous | 1997 |
Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
Topics: Amifostine; Animals; Antineoplastic Agents; Cisplatin; Drug Combinations; Drug Synergism; Female; Humans; Kidney; Liver; Mice; Neoplasm Transplantation; Ovarian Neoplasms; Platinum; Radiation-Protective Agents; Transplantation, Heterologous | 1998 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |